ArticleMedicine2026
Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationaleRenal cell carcinoma is a highly heterogeneous urological malignancy, with clear cell renal cell carcinoma (ccRCC) as the most common pathological subtype. A considerable proportion of patients are diagnosed at advanced stages or experience postoperative recurrence and distant metastasis, leading to poor long-term prognosis. Although targeted therapy and immune checkpoint inhibitors (ICIs) have greatly improved the treatment landscape of advanced ccRCC, optimal sequential and combination treatment strategies for heavily pretreated metastatic patients remain to be further explored. PATIENT CONCERNS: A 49-year-old male patient was diagnosed with stage IV ccRCC complicated with lung metastasis. After palliative nephrectomy and multiple lines of targeted and immunotherapeutic regimens, the patient still suffered from continuous tumor progression, with recurrent pulmonary metastatic lesions, newly occurring adrenal metastasis and brain metastasis, accompanied by clinical symptoms including cough, hemoptysis, and persistent dizziness. DIAGNOSES: The patient was definitively diagnosed with metastatic ccRCC (T1N1M1, Stage IV). Radiological examinations confirmed progressive pulmonary metastases, new right adrenal metastasis, and right frontal lobe brain metastasis after multiple lines of treatment.
interventionsThe patient initially underwent palliative left nephrectomy and sequential sorafenib targeted therapy. After disease progression, intracranial intensity-modulated radiotherapy combined with sunitinib plus interleukin-2 immunotherapy was administered. Following subsequent disease progression, the patient received 4 cycles of camrelizumab combined with bevacizumab, followed by bevacizumab maintenance therapy. Since January 2024, the patient has been treated with tislelizumab plus bevacizumab combination regimen. OUTCOMES: After sequential multi-line individualized treatment, the patient achieved sustained stable disease. The overall survival of the patient has reached approximately 6 years up to the latest follow-up, with favorable long-term survival benefit and well-tolerated treatment safety. LESSONS: For heavily pretreated metastatic ccRCC patients with prior targeted therapy but no previous ICI exposure, ICI combined with bevacizumab is a feasible and effective salvage treatment regimen, which can achieve durable survival benefits. Further prospective clinical studies and long-term follow-up are required to verify the clinical promotion value of this combination strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.